2007; Schmidt et al. 1992). In GBS patients, the level of IFN‐γ in the serum is increased, and in an EAN model, the level of IFN‐γ is associated with the clinical course (Liu et al. 2020; Elkarim et al. 1998). The use of recombinant IFN‐γ could aggravate the clinical symptoms of EAN mice, and treatment with anti‐IFN‐γ antibodies improved clinical outcomes in GBS and EAN models. However, IFN‐γ knockout (KO) in mice could aggravate clinical symptoms by increasing the abundance of Th17 cells (Zhu et al. 2001). Here, IFNG is linked to Guillain-Barre syndrome.